Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differences in failure patterns according to the EGFR mutation status after proton beam therapy for early stage non-small cell lung cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - 1 Aug 2020

Nakamura Masaki, Kageyama Shun-Ichiro, Udagawa Hibiki, Zenke Yoshitaka, Yoh Kiyotaka, Niho Seiji, Hojo Hidehiro, Motegi Atsushi, Kirita Keisuke, Matsumoto Singo, Goto Koichi, Akimoto Tetsuo

Abstract excerpt

We analyzed 135 patients (including 27 EGFR-mutant and 29 EGFR-wild) with T1-3N0M0 non-squamous NSCLC treated by PBT. Considering the 3-year cumulative incidence, the EGFR-mutant group showed a significantly lower infield failure rate (9% vs 27%, p = 0.02) and higher out-of-field failure rate (67% vs 40%, p = 0.02) than the EGFR-wild group.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Staging

Source

Identifiers

PMID: 32387485
DOI: 10.1016/j.radonc.2020.04.056

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Differences in failure patterns according to the EGFR mutation status after proton beam therapy for early stage non-small cell lung cancer.PMID 32387485Read ↗

Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy.Semantic proximity Read ↗

EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis.Semantic proximity Read ↗

Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR Mutation-Positive Lung Cancer with EFGR-TKI treatment: A Prospective, Single Arm, Phase II StudySemantic proximity Read ↗

[Analysis of treatment failure phenotype and prognostic factors of stage Ⅰ non-small cell lung cancer].Semantic proximity Read ↗

Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Advanced therapeutic options and importance of rebiopsy in epidermal growth factor receptor-tyrosine kinase inhibitor-progressed nonsmall cell lung carcinoma patients: An expert opinion.Semantic proximity Read ↗

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study.Semantic proximity Read ↗

EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.